Document is current

Article History

Accepted: 30 December 2024

First Online: 24 January 2025

Declarations

:

: Funding and competing interestsThe authors did not receive support from any organization for the submitted work.C.H. does not have any disclosures. O.S. serves on the editorial boards of Therapeutic Advances in Neurological Disorders, Expert Review of Clinical Immunology, and he is a section editor for Current Treatment Options in Neurology, has served on data monitoring committees for Genentech-Roche, and Novartis without monetary compensation, has advised EMD Serono, Novartis, and Octave Bioscience, receives grant support from EMD Serono, is a 2021 recipient of a Grant for Multiple Sclerosis Innovation (GMSI), Merck KGaA, is funded by a Merit Review grant (federal award document number (FAIN) BX005664-01 from the United States (U.S.) Department of Veterans Affairs, Biomedical Laboratory Research and Development, is funded by RFA-2203-39314 (PI) and RFA-2203-39305 (co-PI) grants from the National Multiple Sclerosis Society (NMSS).B.E.S. is funded as a PI by the Alzheimer’s Association (23AACSF-1026291) and as a Co-I by a Merit grant (federal award document number CX002739-01) from the United States (U.S.) Department of Veterans Affairs.